A novel series of potent and selective EP(4) receptor ligands: facile modulation of agonism and antagonism.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2010.10.106PMID 21126875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.

  2010cited by this paper
• The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.

  2010cited by this paper
• Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.

  2008cited by this paper
• MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis

  2008cited by this paper
• COX-2 inhibitors and cardiovascular risk.

  2007cited by this paper
• Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy.

  2006cited by this paper
• Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.

  2004cited by this paper
• Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase

  2003cited by this paper
• G-Protein-coupled receptors: Lipidated peptides: a therapeutic tool kit

  2002cited by this paper
• Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo

  1996cited by this paper
• Directed lithiation of 1-(tert-butoxycarbonyl)indolines. A convenient route to 7-substituted indolines

  1992cited by this paper

• Revisiting prostaglandin E2: A promising therapeutic target for osteoarthritis.

  2024cites this paper
• Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses.

  2022cites this paper
• Eicosanoid Pathway Modulators: Prostaglandins, Prostacyclin, and Thromboxane

  2021cites this paper
• Grapiprant: A snapshot of the current knowledge

  2021cites this paper
• Pharmacokinetics of grapiprant in goat kids at two different dosing regimens

  2021cites this paper
• Druggable Prostanoid Pathway.

  2020cites this paper
• Aberrant subchondral osteoblastic metabolism modifies NaV1.8 for osteoarthritis

  2020cites this paper
• RhCl3·3H2O-Catalyzed C7-Selective C-H Carbonylation of Indolines with CO and Alcohols.

  2019cites this paper
• Multimodale Therapie der kaninen Osteoarthritis – aktueller Stand und neue Optionen

  2018cites this paper
• Detection and pharmacokinetics of grapiprant following oral administration to exercised Thoroughbred horses.

  2018cites this paper
• Structural features of subtype-selective EP receptor modulators.

  2017cites this paper
• Pharmacokinetics of grapiprant, a selective EP4 prostaglandin PGE2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats

  2017cites this paper
• Pharmacokinetic/pharmacodynamic evaluation of grapiprant in a carrageenan‐induced inflammatory pain model in the rabbit

  2017cites this paper
• Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists.

  2016cites this paper
• Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation

  2015cites this paper
• G-protein coupled receptor expression in medulloblastoma subgroups: Identifying and exploiting molecular targets

  2015cites this paper
• G-protein coupled receptor expression patterns delineate medulloblastoma subgroups

  2013cites this paper
• Prostaglandin EP4 antagonists.

  2013cites this paper
• Potential therapeutic interventions via EP2/EP4 prostaglandin receptors.

  2012cites this paper
• Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor.

  2011cites this paper